Drug Profile
ATX 304
Alternative Names: ATX-304; O 304; O-304XLatest Information Update: 02 Nov 2023
Price :
$50
*
At a glance
- Originator Betagenon
- Class Antihyperglycaemics; Antineoplastics; Benzamides; Cardiovascular therapies; Obesity therapies; Small molecules; Thiadiazoles; Vascular disorder therapies
- Mechanism of Action AMP activated protein kinase stimulants; PCSK9 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Type 2 diabetes mellitus
- Phase I Metabolic disorders
- Clinical Phase Unknown Unspecified
- Preclinical Cardiovascular disorders; Diabetic nephropathies
- No development reported Peripheral arterial disorders
Most Recent Events
- 17 Oct 2023 Amplifier Therapeutics initiates enrolment in a phase Ib trial for Cardiac disorders in European Union
- 17 Oct 2023 Amplifier Therapeutics initiates enrolment in a phase Ib trial for Metabolic disorders in European Union
- 17 Mar 2023 ATX 304 is still in phase I trials for Metabolic disorders in Sweden